Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1α, in a phase I clinical trial in patients with relapsed/refractory breast cancer

Hal E. Broxmeyer, Attilio Orazi, Nancy L. Hague, George W. Sledge, Henrik Rasmussen, Michael S. Gordon

Research output: Contribution to journalArticle

35 Scopus citations

Fingerprint Dive into the research topics of 'Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1α, in a phase I clinical trial in patients with relapsed/refractory breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences